Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HA-WBRT vs SRS for Distant Brain Relapse
NCT04588246Phase 3Terminated
- Sponsor
- NRG Oncology
- Start
- Aug 2021
- Primary completion
- Aug 2024
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by NRG Oncology. Primary endpoint: Percentage of Participants With Neurologic Death at 29.7 months. Started Aug 2021; status: terminated.
Beyond the preview
Go deeper on NCT04588246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04588246.